Skip to main content
ENTROPY NEURODYNAMICS LIMITED logo

ENTROPY NEURODYNAMICS LIMITED — Investor Relations & Filings

Ticker · ENP ISIN · AU0000433583 ASX Professional, scientific and technical activities
Open in API
Filings indexed 393 across all filing types
Latest filing 2026-05-21 Share Issue/Capital Cha…
Country AU Australia
Listing ASX ENP

About ENTROPY NEURODYNAMICS LIMITED

https://entropyneurodynamics.com/

Entropy Neurodynamics Limited focuses on the research and development of computational frameworks and analytical tools derived from information theory and dynamical systems. The company specializes in the study of neurodynamics, exploring the complex, non-linear interactions within neural systems and the application of entropy-based metrics to quantify brain state transitions. Its core activities include the design of algorithms for neural data processing, the modeling of cognitive architectures, and the development of technologies aimed at monitoring or modulating neural activity. By integrating principles of thermodynamics and neuroscience, the firm provides technical solutions for understanding neural information flow and optimizing the performance of both biological and synthetic neural networks.

Recent filings

Filing Released Lang Actions
Release of Securities from Escrow 3 pages 267.4KB
Share Issue/Capital Change Classification · 90% confidence The document is an ASX announcement titled “Release from Escrow” that details the release of restricted securities and subsequent quotation application under ASX Listing Rules. This is not a financial report, earnings release, or management presentation, nor is it an officer certification or proxy material. It constitutes a change in the company’s capital structure/trading status by unlocking shares held in escrow. Under the classification definitions, this aligns with “Share Issue/Capital Change” (SHA).
2026-05-21 English
Notification of cessation of securities - ENP 5 pages 16.3KB
Share Issue/Capital Change Classification · 85% confidence The document is an ASX Appendix 3H “Notification of cessation of securities” form detailing the expiry and cessation of unquoted options (a capital structure change). This is not an earnings, management discussion, or legal update, but rather a shareholder capital change announcement. It therefore fits the Share Issue/Capital Change category as a capital structure amendment.
2026-05-14 English
Change of Director's Interest Notice - JC 2 pages 5.9KB
Director's Dealing Classification · 95% confidence The document is ASX Appendix 3Y “Change of Director’s Interest Notice” under Listing Rule 3.19A.2, detailing the director’s securities holdings, acquisitions, and disposals. This is a report of insider share transactions by a company director, matching the definition of Director’s Dealing (DIRS).
2026-05-13 English
Australian Microcap Investment Conference presentation 21 pages 7.2MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement containing the full slide presentation that will be delivered at the Australian Microcap Investment Conference. It includes forward-looking statements, disclaimers, company overview, and slide‐style content rather than substantive financial data or earnings highlights. This fits the definition of an Investor Presentation (IP).
2026-05-10 English
Entropy files new US patent for IBS program 3 pages 287.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Entropy Neurodynamics dated 5 May 2026. It details the filing of a new US provisional patent application related to their TRP-8803 IBS program, supported by new Phase 2a clinical data. The announcement includes management commentary, investor webinar information, and background on the company and its programs. There are no financial statements, quarterly or annual results, or detailed financial analysis. The document is primarily an update on intellectual property and clinical development progress, typical of a capital/financing or strategic update. It is not a full financial report, earnings release, or regulatory filing. The content fits best under Capital/Financing Update (CAP) as it relates to patent filings which are strategic assets impacting company valuation and financing potential.
2026-05-04 English
TRP 8802 delivers 75% breakthrough response in IBS 9 pages 815.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 4 May 2026 from Entropy Neurodynamics reporting breakthrough clinical results from a Phase 2a trial of TRP-8802 in treatment-resistant IBS patients. It includes detailed clinical trial results, efficacy data, mechanistic validation, strategic implications for a related drug candidate, market opportunity, management commentary, and an investor webinar invitation. The document is not a full annual or interim financial report, nor is it an earnings release or audit report. It is a detailed announcement of clinical trial results and strategic implications, typical of a Capital/Financing Update or clinical development update. There is no indication of a shareholder vote, board changes, or legal proceedings. The document is lengthy (15,000 characters) and contains substantive data and analysis about the clinical trial and its implications. Therefore, the best fitting category is Capital/Financing Update (CAP), as it relates to clinical development progress and strategic positioning relevant to investors and capital markets.
2026-05-03 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.